Adverse reactions in myelography

Area of Science:

• Radiology and Imaging
• Neuroscience
• Pharmacology

Background:

• Iodinated contrast media (CM) are essential in medical imaging.
• Assessing the neural tolerability of CM is crucial for patient safety.
• Nonionic dimers represent a newer class of CM with potentially improved safety profiles.

Purpose of the Study:

• To evaluate the predictive value of animal models for the neural tolerability of iodinated contrast media (CM) in humans.
• To specifically assess the neural tolerability of the nonionic dimer iodixanol compared to other CM.
• To correlate animal experimental findings with clinical outcomes of myelography.

Main Methods:

• Comparison of results from 6 animal experiments (rabbits) on CM effects with 22 clinical trials on post-myelographic adverse reactions.
• Evaluation of excitative and depressive effects of subarachnoidally injected CM in nonanesthetized rabbits.
• Analysis of adverse reactions from clinical myelography involving nonionic monomers (metrizamide, iohexol, iopamidol) and dimers (iotrolan, iodixanol).

Main Results:

• Animal experiments reliably predicted the convulsive effects of CM.
• The animal model did not predict specific non-convulsive adverse reactions but reflected differences in minor reaction frequencies.
• Iodixanol demonstrated expected neural tolerability comparable to iotrolan and better than nonionic monomers.

Conclusions:

• Animal models are useful for predicting the convulsive potential of CM.
• Animal models offer valuable insights into the relative frequencies of minor adverse reactions in clinical settings.
• Iodixanol is anticipated to have favorable neural tolerability, potentially superior to nonionic monomers.